OGNOrganon & Co.
Is it growing?
Growth is fading: revenue shrinking (−2% year on year) and earnings down −71% year on year.
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: −1% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.
All from SEC EDGAR, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is OGN growing?
Organon & Co. has grown revenue −0.22% a year over three years and −0.64% a year over five, with earnings per share compounding at −36%.
Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · shrinking · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- −0.64%
Revenue growth, 5-year rate · −0.22% over three · growth has picked up over the last three years
- Earnings per share, 3-year rate
- −36%
Earnings per share, 3-year rate · revenue −0.22% · earnings lagged revenue: the growth is costing something
- Years of annual history on file
- 7
Years of annual history on file · FY2019 to FY2025, as filed
Details›
- Revenue FY2021
- $6.30B
- Revenue FY2022
- $6.17B
- Revenue FY2023
- $6.26B
- Revenue FY2024
- $6.40B
- Revenue FY2025
- $6.22B
Annual income statements as filed with the SEC.
Drug Manufacturers, General
Ranks #4 of 7 by RyuScore